In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.
A phase 3 randomized trial found that Mim8 prophylaxis significantly reduced bleeding rates compared with on-demand therapy and clotting factor prophylaxis in patients with hemophilia A with or without...
In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
In a retrospective national VA cohort of nearly 1 million Veterans, tobacco smoking duration criteria identified more screening-eligible patients and fewer missed lung cancer diagnoses than pack-year...
In the phase 3 PEAK trial, bezuclastinib plus sunitinib significantly improved median progression-free survival vs sunitinib alone in patients with advanced gastrointestinal stromal tumors after prior...
In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...
In an integrated phase 2 analysis of HPV-associated oropharyngeal cancer, FMISO PET-guided chemoradiotherapy de-escalation was associated with 97% 5-year overall survival in both the 30-Gy and 70-Gy...
A randomized clinical trial evaluated whether a 6-month habit-focused lifestyle program could improve sustained remission of metabolic syndrome at 24 months compared with standard education and activity...
In a phase 3 randomized trial, investigators evaluated whether finerenone added to the background renin–angiotensin system blockade, thereby reducing albuminuria in adults with type 1 diabetes and chronic...
